Cornerstone Pharmaceuticals announced on the Hong Kong Stock Exchange that the Phase Ib clinical trial of its key product CS5001 (ROR1 ADC) in a global multicenter study has successfully completed the enrollment of the first patient. CS5001 is currently the first known ROR1 ADC to observe clinical anti-tumor efficacy in both solid tumors and lymphoma, with its clinical development progress ranking among the top two globally. Clinical data shows that the objective response rate (ORR) of CS5001 as a monotherapy for aggressive and indolent advanced lymphomas is higher than similar competitors, indicating potential for rapid registration and impact on first-line combination treatment patterns.
基石药业：CS5001（ROR1 ADC）全球多中心Ib期临床试验完成首例患者入组
Cornerstone Pharmaceuticals: The global multicenter Phase Ib clinical trial of CS5001 (ROR1 ADC) has successfully completed the enrollment of the first patient.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.